title: A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity.
abstract: Twenty-nine overweight schizophrenic patients maintained on depot neuroleptic injections who wished to lose weight took part in a double-blind, placebo-controlled trial of 30 mg D-fenfluramine. All subjects received dietary advice. Sixteen patients completed the 12-week trial. Rate of weight loss was significantly greater in those taking D-fenfluramine. Side-effects were reported, but no deterioration in mental state was noted.
authors.affiliation: Academic Unit of Human Psychopharmacology, Medical College, St Bartholomew's Hospital.
authors.forename: E
authors.initials: E
authors.lastname: Goodall
authors.forename: C
authors.initials: C
authors.lastname: Oxtoby
authors.forename: R
authors.initials: R
authors.lastname: Richards
authors.forename: G
authors.initials: G
authors.lastname: Watkinson
authors.forename: D
authors.initials: D
authors.lastname: Brown
authors.forename: T
authors.initials: T
authors.lastname: Silverstone
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005277:Fenfluramine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D012559:Schizophrenia / Q000150:complications* / Q000188:drug therapy; D015431:Weight Loss / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D005277:Fenfluramine